OakChart

MAIA Biotechnology Inc

MAIAHealthcare·Biotechnology·USA·Micro·AMEX·Nov 11 • 10:12 AM ET

1.050.00 (0.00%)
2026-11-11 16:19 CET
Market cap
64.83 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-25.12 USD m
Free cash flow, TTM
-25.39 USD m
EPS diluted, TTM
-0.48
P/E
-
Compare

Price

MAIA against its 20, 50 and 200-day averages
2050200earnings
1.001.201.401.7M3.4MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MAIAclose 1.0520-day 1.1150-day 1.20200-day 1.411.05

67.1% under 3.19 on 28 Jan 2026. Last 15 sessions, 19.6% high to low

Profile

MAIA
52-week range, 8% of the way up
0.873.19

MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded on August 3, 2018 and is headquartered in Chicago, IL.

Employees13
IPOJul 28, 2022
Beta0.30
ATR, 14d0.06
Rel volume0.33
Short float4.79%
Insider own16.98%
Inst own22.25%

Snapshot

6 groups

Valuation

Index-
Market Cap64.84M
Enterprise Value43.50M
Income-25.12M
Sales0.00M
Book/sh0.25
Cash/sh0.35
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees13
IPOJul 28, 2022

Ratios

P/E-
Forward P/E0.95
PEG-
P/S-
P/B4.14
P/C3.04
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio3.41
Current Ratio3.41
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.48
EPS next Y1.11
EPS next Q-0.13
EPS this Y22.86%
EPS next Y305.56%
EPS next 5Y-
EPS past 3/5Y26.39% -2.25%
Sales past 3/5Y- -
EPS Y/Y TTM35.05%
Sales Y/Y TTM-
EPS Q/Q56.04%
Sales Q/Q-
EarningsAug 11
EPS/Sales Surpr.-18.18% -

Ownership

Insider Own16.98%
Insider Trans4.05%
Inst Own22.25%
Inst Trans7.30%
ROA-144.03%
ROE-319.77%
ROIC-160.31%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-5.23%
SMA50-12.49%
SMA200-25.56%
Trades-

Technical

Shs Outstand61.74M
Shs Float51.26M
Short Float4.79%
Short Ratio5.49
Short Interest2.45M
52W High3.19 -67.08%
52W Low0.87 20.69%
Volatility6.29% 5.47%
ATR (14)0.06
RSI (14)40.76
Beta0.30
Rel Volume0.33
Avg Volume446.59K
Volume24,767

Performance

Perf Week-7.89%
Perf Month-9.48%
Perf Quarter-21.64%
Perf Half Y-18.60%
Perf YTD-31.37%
Perf Year-6.25%
Perf 3Y-47.24%
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price14.00
Prev Close1.05
Price1.05
Change %0.00%

Peers

Mkt cap
TickerCompanyMkt cap
BDTXBlack Diamond Therapeutics Inc91.64M
CADLCandel Therapeutics Inc719.66M
GERNGeron Corp627.81M
ACRVAcrivon Therapeutics Inc67.60M
NVCTNuvectis Pharma Inc713.57M
CUECue Biopharma Inc143.33M
ONCYOncolytics Biotech Inc48.82M
PDSBPDS Biotechnology Corp107.34M
HURATuHURA Biosciences Inc99.42M
KZIAKazia Therapeutics Limited ADR86.13M

Insider trading

latest 14 of 25
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Vitoc VladChief Executive OfficerSep 14 '26Buy1.3773,000100,0101,049,121Sep 15 06:33 AM
Guerrero RamiroDirectorSep 10 '26Buy1.3237,59549,516773,296Sep 14 09:03 AM
Guerrero RamiroDirectorAug 27 '26Buy1.3978,239108,752689,081Sep 01 04:16 PM
Guerrero RamiroDirectorAug 28 '26Buy1.3546,62062,937735,701Sep 01 04:16 PM
Guerrero RamiroDirectorAug 26 '26Buy1.398,93112,414610,842Sep 01 04:16 PM
Guerrero RamiroDirectorAug 24 '26Buy1.331,7942,386601,911Aug 26 07:56 AM
Guerrero RamiroDirectorAug 20 '26Buy1.3711,89916,302600,117Aug 24 04:09 PM
Vitoc VladChief Executive OfficerJun 01 '26Buy1.3972,700100,886976,121Jun 02 09:02 AM
Smith StanDirectorJun 01 '26Buy1.3475,000100,2001,519,178Jun 02 09:01 AM
Gryaznov SergeiChief Scientific OfficerJun 01 '26Buy1.342,0002,69046,511Jun 02 09:00 AM
Smith StanDirectorDec 22 '25Buy1.2257,18969,9991,421,478Dec 23 08:18 AM
CHAOUKI STEVEN MDirectorDec 22 '25Buy1.2240,84949,999151,873Dec 23 08:16 AM
Louie Ngar YeeDirectorDec 22 '25Buy1.2281,699100,0001,248,888Dec 23 08:14 AM
Smith StanDirectorDec 05 '25Buy1.2013,74016,4414,580Dec 09 04:51 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M

News

latest 14 of 206
  • MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer (GlobeNewswire)
  • MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal (GlobeNewswire)
  • MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer (GlobeNewswire)
  • MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial (GlobeNewswire)
  • MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO (GlobeNewswire)
  • Loading…
  • MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026 (GlobeNewswire)
  • MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial (GlobeNewswire)
  • MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer (GlobeNewswire)
  • MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University (GlobeNewswire) +6.06%
  • MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial (GlobeNewswire)
  • MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial (GlobeNewswire)
  • MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion (GlobeNewswire) +5.93%
  • MAIA Biotechnology Announces Open Market Purchases by CEO and Director (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-11-0.130-0.110-0.1310.000.001
2026Q12026-05-04-0.160-0.180-0.1410.000.001
2025Q42026-03-23-0.100-0.130-0.0940.000.001
2025Q32025-11-04-0.270--0.2680.00--
2025Q22025-08-05-0.180-0.240-0.1770.000.001
2025Q12025-05-05-0.160-0.180-0.1630.000.001
2024Q42025-03-24-0.320-0.320-0.1370.000.002
2024Q32024-11-06-0.355-0.470-0.1150.000.001
2024Q22024-08-19-0.450-0.415-0.4000.000.002
2024Q12024-05-06-0.390-0.390-0.4580.000.002
2023Q42024-03-22-0.390-0.390-0.3680.000.002
2023Q32023-11-07-0.360-0.385-0.3570.000.002
2023Q22023-08-08-0.350-0.380-0.3510.000.002
2023Q12023-05-08-0.380--0.3750.00-2
2022Q42023-03-24-0.425-0.415-0.3780.000.002
2022Q32022-11-09-0.490--0.482---

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-1.750-1.805-1.7480.000.00
2023FY-1.495-1.495-1.4910.000.00
2024FY-1.485-1.485-1.0480.000.00
2025FY-0.700-0.740-0.000.00
2026FY--0.540--0.00
2027FY-1.110--0.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-111000.000.000.00
2026Q3S2026-05-041000.000.000.00
2026Q3S2026-03-231000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00
2026Q3S2025-09-301000.000.000.00
2026Q3S2025-09-291000.000.000.00
2026Q3S2025-09-281000.000.000.00
2026Q3S2025-09-271000.000.000.00
2026Q3S2025-09-261000.000.000.00
2026Q3S2025-09-251000.000.000.00

Estimate history

EPS, annual-0.611-0.624-1.176-1.748-1.491-1.048-0.697-0.4834
Period2019202020212022202320242025TTM
EPS, quarterly-0.115-0.137-0.163-0.177-0.268-0.094-0.141-0.131-0.118
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00000000
Period2019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual10.63610.63610.63610.95616.98626.15838.62461.742
Period2019202020212022202320242025MRQ
Shares, quarterly23.96726.15829.58731.81834.45138.62460.67160.81761.742
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other27.6124.2717.0420.3615.397.796.986.92
Research and Development16.3814.5510.0911.299.253.501.411.91
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-27.61-24.27-17.04-20.36-15.39-7.79-6.98-6.92
Interest Expense0.000.000.000.010.010.830.03-
Unusual Expense-0.79-1.206.60-0.380.693.97-0.050.00
Net Income Before Taxes-25.12-22.40-23.33-19.95-16.08-12.58-6.96-6.92
Income Taxes0.000.00-0.08-0.18-0.310.000.000.00
Consolidated Net Income-25.12-22.40-23.25-19.77-15.77-12.58-6.96-6.92
Net Income From Continuing Operations-25.12-22.40-23.25-19.77-15.77-12.50-6.64-6.49
Net Income-25.12-22.40-23.25-19.77-16.22-12.50-6.64-6.49
EPS (Recurring)-0.42-0.72-0.84-1.51-1.70-0.91-0.63-0.61
EPS (Basic, Before Extraordinaries)-0.48-0.70-1.05-1.49-1.75-1.18-0.62-0.61
EPS (Diluted)-0.48-0.70-1.05-1.49-1.75-1.18-0.62-0.61
EBITDA-27.61-24.27-17.04-20.36-15.39-7.79-6.98-6.92
Non-Operating Income (Expense)1.700.680.310.030.000.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.072.631.913.092.322.463.894.14
Shares Outstanding61.7438.6226.1616.9910.9610.6410.6410.64
Market Capitalization64.8364.8350.1616.1038.4238.42--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other8.028.326.954.329.365.175.435.03
Research and Development5.345.643.531.886.363.113.203.00
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-8.02-8.32-6.95-4.32-9.36-5.17-5.43-5.03
Interest Expense0.000.000.000.000.000.000.00-
Unusual Expense-0.350.07-0.25-0.25-0.380.26-0.83-1.37
Net Income Before Taxes-7.18-7.94-6.37-3.63-8.90-5.35-4.52-3.60
Income Taxes0.000.000.000.000.000.000.00-0.03
Consolidated Net Income-7.18-7.94-6.37-3.63-8.90-5.35-4.52-3.57
Net Income From Continuing Operations-7.18-7.94-6.37-3.63-8.90-5.35-4.52-3.57
Net Income-7.18-7.94-6.37-3.63-8.90-5.35-4.52-3.57
EPS (Recurring)-0.12-0.13-0.14-0.10-0.28-0.17-0.18-0.17
EPS (Basic, Before Extraordinaries)-0.12-0.13-0.14-0.09-0.27-0.18-0.16-0.14
EPS (Diluted)-0.12-0.13-0.14-0.09-0.27-0.18-0.16-0.14
EBITDA-8.02-8.32-6.95-4.32-9.36-5.17-5.43-5.03
Non-Operating Income (Expense)0.500.440.330.430.080.080.080.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.880.720.650.810.650.800.370.69
Shares Outstanding61.7460.8260.6738.6234.4531.8229.5926.16
Market Capitalization64.8387.5584.9456.6650.8154.5545.2750.16

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments8.669.607.1510.9510.570.661.71
Short Term Receivables0.000.080.140.300.000.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets1.040.470.270.550.100.080.02
Total Current Assets9.7010.157.5611.8110.670.751.73
Net Property, Plant & Equipment0.000.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.000.00
Long-Term Note Receivable----0.00--
Intangible Assets-----0.000.00
Other Assets0.000.000.000.210.650.000.00
Total Assets9.7010.167.5712.0211.330.751.73
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.030.03
Accounts Payable2.041.511.641.170.960.200.17
Other Current Liabilities3.802.323.302.101.191.460.18
Total Current Liabilities5.843.834.943.272.151.690.37
Long Term Debt0.000.000.000.000.000.560.01
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities1.492.692.150.250.000.110.03
Total Liabilities7.336.527.093.512.152.360.41
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity2.383.630.488.519.18-3.34-0.17
Total Shareholders Equity2.383.630.488.519.18-3.34-0.17
Accumulated Minority Interest0.000.000.000.000.001.721.50
Total Equity2.383.630.488.519.18-1.621.32
Total Liabilities & Stockholders Equity9.7010.167.5712.0211.330.751.73
Book Value Per Share0.060.140.030.780.86-0.31-0.02
Tangible Book Value Per Share0.060.140.030.780.86-0.31-0.02
Full-Time Employees131313189--
Price to Book Ratio4.1429.325.863.123.12--
Return on Assets-225.54-262.44-201.88-135.07-207.13-534.99-
Return on Equity-745.24-1,131.02-440.12-178.29-427.84--
Return on Invested Capital-942.65-639.81-4,140.83-185.35-136.19--
Quick Ratio1.662.651.533.614.970.444.63
Current Ratio1.662.651.533.614.970.444.63

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-25.12-22.40-23.25-19.77-15.77-12.58-6.96-6.92
Other Funds (Non Cash)3.132.058.793.623.327.333.865.09
Funds from Operations-21.99-20.34-14.47-16.16-12.45-5.25-3.10-1.83
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-3.401.50-1.243.090.791.131.250.27
Cash from Operating Activities-25.39-18.84-15.70-13.07-11.66-4.12-1.84-1.57
Capital Expenditures0.000.000.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.19
Purchase or Sale of Investments0.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.000.000.19
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock35.7917.9118.975.7512.046.28-0.012.09
Repurchase of Common Pref Stock0.000.000.000.000.000.00-0.060.00
Sale of Common Pref Stock35.7917.9118.975.7512.046.280.052.09
Proceedsfrom Stock Options35.7517.0018.755.7511.575.740.052.09
Issuance or Reduction of Debt, Net0.000.000.000.000.007.430.610.01
Change in Long Term Debt0.000.000.000.000.007.430.000.00
Issuance of Long Term Debt0.000.000.000.000.007.430.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00-0.803.520.000.320.200.12
Other Financing Activities Uses0.000.00-0.80-2.150.000.000.000.00
Cash from Financing Activities35.7917.9118.189.2712.0414.030.802.22
Exchange Rate Effect0.05-0.01-0.02-0.00-0.00---
Net Change in Cash10.45-0.942.45-3.800.389.91-1.050.84
Free Cash Flow-25.39-18.84-15.70-13.07-11.66-4.12-1.84-1.57
Preferred Dividends (Cash Flow)-0.000.000.00-0.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments21.3427.6034.418.6610.8910.14
Short Term Receivables0.000.000.000.000.080.08
Inventories0.000.000.000.000.000.00
Other Current Assets0.760.640.901.040.780.82
Total Current Assets22.1028.2435.329.7011.7511.04
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Other Assets0.000.000.010.000.030.00
Total Assets23.1028.2435.329.7011.7811.05
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable4.122.842.982.043.181.72
Other Current Liabilities2.353.423.343.806.823.32
Total Current Liabilities6.476.266.325.849.995.04
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.961.311.241.491.752.13
Total Liabilities7.437.577.567.3311.747.17
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity15.6720.6827.762.380.043.88
Total Shareholders Equity15.6720.6827.762.380.043.88
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity15.6720.6827.762.380.043.88
Total Liabilities & Stockholders Equity23.1028.2435.329.7011.7811.05
Book Value Per Share0.250.340.460.060.000.12
Tangible Book Value Per Share0.250.340.460.060.000.12
Full-Time Employees---13--
Price to Book Ratio4.144.243.061,264.4612.6410.78
Return on Assets-144.03-136.67-102.78-225.54-212.50-140.23
Return on Equity-319.77-218.68-148.29-745.24-2,691.06-459.53
Return on Invested Capital-45.81-38.42-22.94-152.73-21,365.94-137.93
Quick Ratio3.414.515.591.661.182.19
Current Ratio3.414.515.591.661.182.19

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-7.18-7.94-6.37-3.63-8.90-5.35
Other Funds (Non Cash)0.770.990.440.930.451.13
Funds from Operations-6.41-6.95-5.93-2.70-8.45-4.22
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.100.200.62-4.324.960.09
Cash from Operating Activities-6.31-6.75-5.31-7.02-3.49-4.14
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.00-0.0731.054.804.233.41
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.00-0.0731.054.804.233.41
Proceedsfrom Stock Options0.00-0.0731.014.803.663.08
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.00-0.0731.054.804.233.41
Exchange Rate Effect0.05-0.000.01-0.02-0.000.01
Net Change in Cash-6.26-6.8225.76-2.230.75-0.72
Free Cash Flow-6.31-6.75-5.31-7.02-3.49-4.14

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.79%2.5M51.3M458.25K
2026-10-154.92%2.5M51.3M492.35K
2026-09-305.25%2.7M51.3M536.78K
2026-09-154.16%2.1M50.5M501.76K
2026-08-314.64%2.3M50.6M649.59K
2026-08-145.42%2.7M50.8M678.52K
2026-07-316.04%3.1M50.7M714.96K
2026-07-155.75%2.9M50.7M750.13K
2026-06-306.72%3.4M50.7M752.14K
2026-06-156.27%3.2M50.7M782.57K
2026-05-295.82%3.0M50.7M846.98K
2026-05-155.55%2.8M50.9M865.60K
2026-04-306.24%3.2M50.8M882.23K
2026-04-155.59%2.8M50.8M1.12M
2026-03-314.97%2.3M46.3M1.07M
2026-03-136.15%1.8M29.5M1.04M
2026-02-278.34%2.5M29.5M970.02K
2026-02-137.38%2.1M28.3M904.83K
2026-01-307.01%2.0M28.3M841.28K
2026-01-155.77%1.6M28.3M693.96K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-07424B3SEC
2026-10-06EFFECTEffectiveness filing by commission orderSEC
2026-10-068-KCurrent report2026-10-06SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-02424B3SEC
2026-09-25S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-28EFFECTEffectiveness filing by commission orderSEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-24SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-21S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-06-01SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09149.53K200
2026-08202.79K500
2026-070000
2026-06203.78K300
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-12236.44K400
2025-11193.35K1100

Institutional holders

Manager% owned
Solas Capital Management, LLC4.98%
Alyeska Investment Group, L.P.4.11%
VANGUARD CAPITAL MANAGEMENT LLC3.97%
683 Capital Management, LLC1.75%
Centric Wealth Management1.31%
GEODE CAPITAL MANAGEMENT, LLC0.96%
Cable Car Capital, LP0.85%
Bleichroeder LP0.82%
RENAISSANCE TECHNOLOGIES LLC0.68%
BlackRock, Inc.0.66%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.76%
VANGUARD EXTENDED MARKET INDEX FUND1.10%
Fidelity Extended Market Index Fund0.47%
iShares Micro-Cap ETF0.29%
Fidelity Total Market Index Fund0.14%
Fidelity Series Total Market Index Fund0.14%
Ultra-Small Company Market Fund0.12%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.07%
VANGUARD BALANCED INDEX FUND0.05%
1290 VT Micro Cap Portfolio0.02%

OakChart. MAIA. Cached 15 minutes.

Some panels did not load: ratings.